Cardiovascular, metabolic and venous diseases
We intend to maintain our leading position in cardiometabolism by taking a strategic and innovative approach to managing the life cycle of our medicines. We capitalize on our expertise in incremental innovation, in particular by developing Single Pill Combinations. We continue to offer solid support to patients by developing innovative digital services to refine diagnoses, understanding of chronic illnesses and improve therapeutic adherence. Similarly, we have long been involved in treating Type 2 diabetes, which accounts for around 90% of diabetes cases in the world. Furthermore, we work alongside health care professionals and patients to better understand venous insufficiency and treat the symptoms.
About Servier
Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, a source of inspiration every day.
Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria. In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine. Headquartered in France.
Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.
More information on the new Group website: servier.com
